South China Morning Post

AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows

Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm’s flagship cancer drug, while a new deal from US giant Merck further underscored the sector’s global momentum amid easing fears of US curbs. AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akeso’s immunotherapy drug ivonescimab outside China. Summit and AstraZeneca would.

By South China Morning Post

1 min read
AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows
AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Startups & Entrepreneurship

Related Insights